Ascelia Pharma AB (publ) Total Liabilities

Latest as of September 2025: Skr22.01 Million SEK ≈ $2.37 Million USD

Ascelia Pharma AB (publ) total liabilities. Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has total liabilities worth Skr22.01 Million SEK (≈ $2.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ascelia Pharma AB (publ) liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Ascelia Pharma AB (publ) (2016–2024)

Total liabilities of Ascelia Pharma AB (publ) from 2016 to 2024. This chart illustrates how Ascelia Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Ascelia Pharma AB (publ) to see how much of total assets are deployed in long-term investments.

Ascelia Pharma AB (publ) Competitors by Total Liabilities

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
UET United Electronic Technology AG XETRA:CFC	Germany	€49.88 Million
Rockworth Public Company Limited BK:ROCK	Thailand	฿526.74 Million
Multi Ways Holdings Ltd NYSE MKT:MWG	USA	$32.73 Million
Patkol Public Company Limited BK:PK	Thailand	฿1.48 Billion
Norwood Systems Ltd AU:NOR	Australia	AU$1.63 Million
Euro Manganese Inc AU:EMN	Australia	AU$34.27 Million
DTI Group Ltd AU:DTI	Australia	AU$5.64 Million
NB Private Equity Partners Ltd LSE:NBPE	UK	GBX96.67 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Ascelia Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ascelia Pharma AB (publ) assets under control.

Liquidity & Leverage Metrics

Ascelia Pharma AB (publ) Total Liabilities Ratios Explained

Ascelia Pharma AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.60	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.19	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.16	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascelia Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascelia Pharma AB (publ) (2016–2024)

The table below shows the annual total liabilities of Ascelia Pharma AB (publ) from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr61.98 Million ≈ $6.67 Million	+386.32%
2023-12-31	Skr12.74 Million ≈ $1.37 Million	-66.21%
2022-12-31	Skr37.71 Million ≈ $4.06 Million	+46.97%
2021-12-31	Skr25.66 Million ≈ $2.76 Million	+32.82%
2020-12-31	Skr19.32 Million ≈ $2.08 Million	+46.75%
2019-12-31	Skr13.16 Million ≈ $1.42 Million	+16.03%
2018-12-31	Skr11.35 Million ≈ $1.22 Million	+156.73%
2017-12-31	Skr4.42 Million ≈ $475.55K	+58.33%
2016-12-31	Skr2.79 Million ≈ $300.36K	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$6.98 Million

Skr64.83 Million SEK

Market Cap Rank

#27781 Global

#605 in Sweden

Share Price

Skr0.51

Change (1 day)

-5.02%

52-Week Range

Skr0.48 - Skr3.43

All Time High

Skr900.24